Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
News provided by
Share this article
Share this article
SAN DIEGO, May 26, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 15 U.S. sites as of May 14, 2021.
The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara s arm of
Top 10 Voluptuous Facts About Breast Implants listverse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from listverse.com Daily Mail and Mail on Sunday newspapers.
Search jobs 10-May-2021 Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021
Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022
Company to host conference call at 8am ET
CAMBRIDGE, Mass. (BUSINESS WIRE)
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company’s Biologics License Application (BLA) for the Company’s lead program, Vicineum, is currently under Priority Review with the Food and Drug Administration (FDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a target Prescription Drug User Fee Act (PDUFA) da
What Message Does the Government Promoting AYUSH 64 Today Send? 10/05/2021
A bottle of AYUSH 64 tablets. Image: Amazon.in
On April 29, the Union Ministry of AYUSH1announced that AYUSH 64, “a poly-herbal formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS),” could help meaningfully treat “asymptomatic, mild and moderate COVID-19 infections as an adjunct to standard care”.
Standard care, technically ‘standard of care’, according to the US National Cancer Institute, is “treatment that experts agree is appropriate, accepted, and widely used.”
The press release in which the government made the announcement claimed that researchers had conducted a randomised controlled clinical trial with 70 participants in each arm (placebo arm and treatment arm) at three centres. They had reportedly demonstrated “significant improvement” and a lower “period of hospitalisation” as compared to treatment by the standard of care alone
Share:
Interim Analysis of Second Confirmatory Phase 3 Study in Fibromyalgia
Expected in Third Quarter 2021
Deep Pipeline Progressing with Three Central Nervous System
(CNS) Programs Expected to Enter Phase 2 Trials This Year
At March 31, 2021, Cash and Cash Equivalents Totaled Approximately $164 Million
CHATHAM, N.J., May 10, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent operational highlights. Tonix possesses a deep pipeline of high-value programs ranging from preclinical to mid-Phase 3 development, with three CNS programs poised to enter Phase 2 trials this year, said Seth Lederman, M.D., President and Chief Executive Officer. Our strategy is to in-license, acquire or internally invent high impact therapeutic programs which we can validate, de-risk and advance